Conjugate And Polysaccharide Vaccines Compared With Polysaccharide Vaccine In Hiv-Infected Adults
Recruitment status was Recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Randomised study comparing two pneumococcal vaccination strategies in HIV-infected adults with moderate immunossupression (CD4 between 200 and 500 cells/uL and viral load under 5logs), one with conjugated heptavalent vaccine(Prevenar, Wyeth-Lederle) followed by polysaccharide vaccine 4 weeks after (Aventis-Pasteur), and two with one dose of polysaccharide vaccine. Determination of secondary effects related to both vaccines and determination of antibody concentration (ELISA) and avidity (ELISA with thiocyanate) and opsonophagocytosis killing activity against the seven serotypes included in the heptavalent vaccine before vaccination, at 4 weeks, at 8 weeks, at48 weeks and 96 weeks. A sample of 220 HIV-infected adults (110 in each group) will be needed to detect differences of 10% for a type I error o 5% for a limited population of 2500 HIV-infected adults. The main hypothesis are :the immunogenicity of pneumococcal vaccination with conjugate and polysaccharide vaccines is superior to immunogenicity induced by polysaccharide vaccination alone(antibody concentration), the avidity and opsonophagocytosis induced by two vaccines is better than the one after polysaccharide vaccine alone, both vaccinations are safe.
| Condition | Intervention | Phase |
|---|---|---|
|
Pneumococcal Vaccines HIV HIV Infections |
Biological: Prevenar and Pneumo23 |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Prevention |
| Official Title: | A Sequential Vaccination Strategy With Conjugated and Polysaccharide Pneumococcal Vaccines Compared With Polysaccharide Vaccine in HIV- Infected Adults. |
- Antibody response in terms of antibody concentration at 4,8,48 and 69 weeks of vaccination [ Time Frame: 4, 8, 48 and 96 weeks of vaccination ] [ Designated as safety issue: No ]
- Avidity of the antibodies induced in the two vaccination groups before and at 4 ,8 , 48 and 96 weeks of vaccination [ Time Frame: 4 , 8 ,48 and 96 weeks after vaccintation ] [ Designated as safety issue: No ]
- safety of both vaccines [ Time Frame: 3 days ] [ Designated as safety issue: Yes ]
- risk factors associated to a good vaccine response [ Time Frame: 8 weeks, 48 weeks, 96 weeks ] [ Designated as safety issue: No ]
- opsonophagocytic activity against the seven polysaccharides before, and after 4,8,48 and 96 weeks of vaccination [ Time Frame: 4,8,48 and 96 weeks ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 220 |
| Study Start Date: | December 2007 |
| Estimated Study Completion Date: | April 2010 |
| Estimated Primary Completion Date: | April 2008 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: two vaccines
people allocated to arm two vaccines will receive one dose of heptavalent pneumococcal conjugate vaccine at day 0 and 23-valent polysaccharide vaccine at week4 , 110 HIV-infected people will be included Intervention: administration of two vaccines
|
Biological: Prevenar and Pneumo23
Two vaccines: participants will receive via intramuscular in deltoid one dose of conjugated heptavalent vaccine at day 0 (Prevenar, Wyeth-lederle)and one dose of 23valent polysaccharide vaccine (Pneumo23, AventisPasteur)at week4 One vaccine:participants will receive only one dose of 23valent polysaccharide vaccine at day 0.
Other Names:
|
|
Experimental: One vaccine
people allocated to arm one will receive only one doses of pneumococcal polysaccharide 23-valent vaccine. 110 HIV-infected adults will be included in this arm Intervention: administration of one vaccine
|
Biological: Prevenar and Pneumo23
Two vaccines: participants will receive via intramuscular in deltoid one dose of conjugated heptavalent vaccine at day 0 (Prevenar, Wyeth-lederle)and one dose of 23valent polysaccharide vaccine (Pneumo23, AventisPasteur)at week4 One vaccine:participants will receive only one dose of 23valent polysaccharide vaccine at day 0.
Other Names:
|
Detailed Description:
Randomised study comparing two pneumococcal vaccination strategies in HIV-infected adults with moderate immunossupression (CD4 between 200 and 500 cells/uL and viral load under 5logs), one with conjugated heptavalent vaccine(Prevenar, Wyeth-Lederle) followed by polysaccharide vaccine 4 weeks after (Aventis-Pasteur), and two with one dose of polysaccharide vaccine. A sample of 220 HIV-infected adults will be randomised to receive twe strategy one(110 patients) one dose of heptavalent conjugated vaccine at day 0 and one dose of polysaccharide vaccine at week 4 (in deltoid muscle); or strategy two (110 patients) one dose of polysaccharide vaccine at day 0. Secondary effects to the vaccines will be evaluated by phone interview 3 days after vaccinations.
Blood samples will be taken at day 0(before the first vaccine), at week 4 before the polysaccharide in the group one, and 4 weeks after the polysaccharide in the group two) and at week 8 in the group one, and at weeks 48 and 96 in both groups Antibody concentration , avidity, and opsonophagocytic killing activity will be measured in all the samples for serotypes 4,14,19F,23F,6B,18C,9V.
Antibody concentration , avidity, and opsonophagocytic killing activity will be compared between both vaccine groups, and between prevaccination and at 4,8, 48 and 96 weeks of vaccination. Risk factors associated to good antibody response (antibody duplication and antibody duplication plus achieve a level above 1ug/ml)will be measured at 8, 48 and96 weeks.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- HIV-infected adults with CD4 between 200 and 500 cels/ul and viral load under 5 logarithm
Exclusion Criteria:
- previous pneumococcal vaccine, pregnancy, advanced renal or liver disease, other vaccine or antibiotics 6 weeks before, other immunosuppression, immunoglobulins or investigation drugs
Contacts and LocationsPlease refer to this study by its ClinicalTrials.gov identifier: NCT00999739
| Contact: maria penaranda, physician | 0034971175371 | maria.penaranda@ssib.es | |
| Contact: antonio payeras, physician | 0034971175371 | a.payeras@hsll.es |
| Spain | |
| Hospital Son Dureta | Recruiting |
| Palma de Mallorca, Illes Balears, Spain, 07014 | |
| Contact: Maria Penaranda, physician 0034971175371 maria.penaranda@ssib.es | |
| Principal Investigator: maria penaranda, physician | |
| Hospital Son Llatzer | Recruiting |
| Palma de Mallorca, Illes Balears, Spain, 07014 | |
| Contact: antonio payeras, physician 0037971175371 a.payeras@hsll.es | |
| Principal Investigator: antonio payeras, physician | |
| Principal Investigator: | maria penaranda, physician | Hospital Son Dureta | |
| Principal Investigator: | antonio payeras, physician | Hospital Son Llatzer |
More Information
No publications provided by Hospital Universitari Son Dureta
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Maria Penaranda, Hospital Son Dureta |
| ClinicalTrials.gov Identifier: | NCT00999739 History of Changes |
| Other Study ID Numbers: | Maria Penaranda |
| Study First Received: | October 21, 2009 |
| Last Updated: | November 6, 2009 |
| Health Authority: | Spain: Comité Ético de Investigación Clínica Spain: Ethics Committee |
Keywords provided by Hospital Universitari Son Dureta:
|
pneumococcal vaccines HIV antibody response |
antibody affinity Antibody formation Phagocytosis |
ClinicalTrials.gov processed this record on March 01, 2015